lenalidomide has been researched along with Aggressive Systemic Mastocytosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dahmash, F; Elmaagacli, AH; Huber, M; Jehn, C; Niggemann, C; Salwender, H; Shikova, Y; Singh, A; Vierbuchen, M | 1 |
| Belli, CB; Larripa, IB; Lincango Yupanki, M; Metrebian, F; Narbaitz, M; Rahhal, M; Rocca, GS; Sarmiento, M; Zubieta, M | 1 |
| Akin, C; Ferenc, V; Kluin-Nelemans, HC; Peters, WG; Valent, P; van Doormaal, JJ; van Iperen, C | 1 |
3 other study(ies) available for lenalidomide and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.
Topics: Antibodies, Monoclonal, Humanized; Family; Humans; Lenalidomide; Lymphocyte Activation; Mastocytosis, Systemic; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family | 2020 |
Efficacy of lenalidomide in a patient with systemic mastocytosis associated with
Topics: Humans; Lenalidomide; Mastocytosis, Systemic; Mutation; Myelodysplastic Syndromes; Phosphoproteins; RNA Splicing Factors | 2021 |
Lenalidomide therapy in systemic mastocytosis.
Topics: Aged; Female; Humans; Lenalidomide; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2009 |